(6-Chloroimidazo[1,2-A]pyrimidin-3-YL)methanamine | 944906-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并[1，2-a]嘧啶
• 英文名称: (6-Chloroimidazo[1,2-A]pyrimidin-3-YL)methanamine
• CAS: 944906-62-1
• 化学式: C₇H₇ClN₄
• mdl: MFCD09994543
• 分子量: 182.61
• InChiKey: NXJGKQSSYCHBIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Therapeutic inhibitory compounds
  申请人：LifeSci Pharmaceuticals, Inc.

  公开号：US10023557B2

  公开（公告）日：2018-07-17

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

  本文提供的杂环衍生物化合物和药物组合物包含所述化合物，可用于抑制血浆卡利克林。此外，所述化合物和组合物还可用于治疗与血浆卡利克酶抑制作用有关的疾病，如血管性水肿等。
• THERAPEUTIC INHIBITORY COMPOUNDS
  申请人：LifeSci Pharmaceuticals, Inc.

  公开号：US20170029406A1

  公开（公告）日：2017-02-02

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
• [EN] THERAPEUTIC INHIBITORY COMPOUDS<br/>[FR] COMPOSÉS INHIBITEURS THÉRAPEUTIQUES
  申请人：LIFESCI PHARMACEUTICALS INC

  公开号：WO2017001924A1

  公开（公告）日：2017-01-05

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.